首页 | 本学科首页   官方微博 | 高级检索  
     

利伐沙班用于急性肺栓塞的抗凝效果及对血清Hcy、BNP、TnI与D-D水平的影响
引用本文:贾 娟,薛世民,张王锋,樊 平,徐 宁. 利伐沙班用于急性肺栓塞的抗凝效果及对血清Hcy、BNP、TnI与D-D水平的影响[J]. 现代生物医学进展, 2019, 19(15): 2933-2936
作者姓名:贾 娟  薛世民  张王锋  樊 平  徐 宁
作者单位:榆林市第二医院呼吸内科;西安交通大学医学部附属医院呼吸内科;陕西省中医院肾病科;榆林市第二医院重症医学科
基金项目:陕西省科学技术厅重点研发计划项目(2017SF-207)
摘    要:目的:探讨利伐沙班用于急性肺栓塞的抗凝效果及对血清脑钠肽(Brain natriuretic peptide,BNP)、肌钙蛋白I (Troponin I,TnI)、D-二聚体(D-Dimer,D-D)、同型半胱氨酸(homocysteine,Hcy)水平的影响。方法:选择2014年2月至2017年12月在我院进行治疗的(高)中危组急性肺栓塞患者106例,并将其随机分为观察组和对照组。对照组皮下注射低分子肝素钙搭配华法林治疗,观察组予以利伐沙班治疗,观察和比较两组患者的临床疗效、治疗前后血清BNP、TnI、D-D、Hcy水平的变化及不良反应的发生情况。结果:治疗后,观察组患者总有效率为94.37%,显著高于对照组(42.10%,P0.05);观察组患者血清BNP、TnI、D-D、Hcy及肺动脉收缩压水平均显著低于对照组(P0.05),而动脉收缩压、动脉血氧分压水平较对照组水平显著升高(P0.05)。结论:利伐沙班应用于治疗急性肺栓塞的抗凝效果显著优于低分子肝素钙搭配华法林治疗,其可有效降低患者血清BNP、TnI、D-D、Hcy水平以及肺动脉收缩压。

关 键 词:利伐沙班;急性肺栓塞;抗凝;同型半胱氨酸;脑钠肽;肌钙蛋白;D-二聚体
收稿时间:2019-01-25
修稿时间:2019-02-20

The Anticoagulant Effect of Rivaroxaban on Acute Pulmonary Embolism and its Effects on the Serum Hcy, BNP, TnI and D-D Levels
JIA Juan,XUE Shi-min,ZHANG Wang-feng,FAN Ping,XU Ning. The Anticoagulant Effect of Rivaroxaban on Acute Pulmonary Embolism and its Effects on the Serum Hcy, BNP, TnI and D-D Levels[J]. Progress in Modern Biomedicine, 2019, 19(15): 2933-2936
Authors:JIA Juan  XUE Shi-min  ZHANG Wang-feng  FAN Ping  XU Ning
Affiliation:Department of respiratory medicine, Yulin Second Hospital, Yulin, Shaanxi, 719000, China;Department of Respiratory Medicine, Department of Medicine, Xi''an Jiaotong University, Yulin, Shaanxi, 719000, China;Department of Nephrology, Shaanxi Hospital of traditional Chinese Medicine, Xi''an, Shaanxi, 710003, China; Department of severe Medicine, The second Hospital of Yulin City, Yulin, Shaanxi, 719000, China
Abstract:ABSTRACT Objective: To study the anticoagulant effect of rivaroxaban on the acute pulmonary embolism and its effects on the serum Hcy, BNP, TnI and D-D levels. Methods: 106 patients with acute pulmonary embolism who were treated from February 2014 to December 2016 were selected as the research objects. The patients were randomly divided into the observation group and the control group, the control group was subcutaneously injected with low molecular heparin calcium, and the observation group was combined with rivaroxaban on the basis of control group. The changes of serum levels of BNP, TnI, D-D, Hcy before and after treatment and incidence of adverse events were compared between two groups. Results: After treatment, the total effective rate was 94.37% in the observation group, which was significantly higher than that of the control group(42.10%, P<0.05); the serum BNP, TnI, DD, Hcy and systolic blood pressure levels in the observation group were significantly lower than those in the control group (P<0.05), while the levels of arterial systolic and arterial oxygen pressure were significantly higher than those in the control group(P<0.05). Conclusion: The anticoagulant effect of rivaroxaban is significantly better than low molecular heparin calcium combined with warfarin in the treatment of acute pulmonary embolism, which can effectively reduce the serum BNP, TnI, d-d, Hcy levels and pulmonary artery systolic pressure of patients.
Keywords:Rivaroxaban   Acute pulmonary embolism   Anticoagulation   Homocysteine   Brain natriuretic peptide   Troponin   D-dimer
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号